In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Inc.

www.biogen.com

Latest From Biogen Inc.

Australia Considers Identifying Drugs Filed For Approval

The Therapeutic Goods Administration wants to know whether, and how, it should disclose the fact that a medicine has been accepted for regulatory review. It has put several options to stakeholders, including disclosure for all medicines or only certain kinds, or keeping the current practice of “neither confirm nor deny.”
Approvals Drug Review

China - The Next Promised Land For Korean Biosimilars?

Biosimilar specialists Celltrion and Samsung Bioepis are poised to start competing in China, which they see as another promising market for their biosimilars amid the Chinese government's increasing policy support for biologics and generics, and rising competition elsewhere. Part of their tailored entry approach includes striking deals with local partners.

Biosimilars Business Strategies

VC Playbook: As China Looms, Sofinnova Partners Keeps The Faith In A Resilient Europe

In this first installment of VC Playbook, a new series profiling venture capital groups in biopharma and medtech, In Vivo talks to Antoine Papiernik, managing partner and chair of Sofinnova Partners – Europe’s largest and oldest VC devoted to the life sciences, with €2 billion under management.

Leadership Financing

Roche Makes Case For Its Oral SMA Drug Risdiplam As Filings Beckon

Novartis may be turning up the rhetoric in spinal muscular atrophy as its cutting-edge gene therapy Zolgensma approaches a market currently enjoyed solely by Biogen’s Spinraza, but Roche is upbeat about the potential of its investigational oral product, risdiplam, to weigh in.

Clinical Trials Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Cardiovascular
  • Immune Disorders
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Biogen Idec Inc.
  • Biogen Inc.
  • Idec Pharmaceutical Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Biogen Inc.
  • Senior Management
  • Michel Vounatsos, CEO
    Jeffrey Capello, EVP, CFO
    Alfred W Sandrock, Jr., MD, PhD, EVP, CMO
    Michael Ehlers, MD, PhD, EVP, R&D
    Daniel Karp, EVP, Corp. Dev.
    Chirfi Guindo, EVP & Head, Global Mktg.
  • Contact Info
  • Biogen Inc.
    Phone: (617) 679-2000
    225 Binney St.
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register